Chronic Lymphocytic Leukemia | Specialty

Maintenance Therapy in Chronic Lymphocytic Leukemia

January 16th 2015

Role of Transplantation in High-Risk CLL

January 16th 2015

Optimizing Treatment With Ibrutinib in High-Risk CLL

January 16th 2015

Safety and Efficacy of Obinutuzumab in CLL

January 16th 2015

First-Line Treatment Selection in CLL

January 16th 2015

Introduction: Upfront Treatment in Patients With CLL

January 16th 2015

FDA Updates Obinutuzumab Frontline CLL Label

December 25th 2014

The FDA has updated the label for obinutuzumab plus chlorambucil to include data from stage 2 of the phase III CLL11 study, which detailed an unprecedented improvement in progression-free survival compared with rituximab plus chlorambucil as a frontline treatment for patients with chronic lymphocytic leukemia.

Frontline Idelalisib Monotherapy Yields High Response Rates in Older Patients With CLL, SLL

December 7th 2014

Idelalisib monotherapy shows activity in treatment-naïve patients ≥65 years with CLL or SLL, with nearly 90% of patients enrolled in a phase II study demonstrating a partial response.

Dr. Jain on the Combination of Idelalisib and Rituximab for Older Patients With CLL

November 26th 2014

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety of the combination of idelalisib and rituximab for older patients with chronic lymphocytic leukemia.

Dr. Brody Discusses Exciting Therapies for Lymphomas and CLL

November 24th 2014

Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).

Juno Files for IPO as CAR Therapies Continue to Advance

November 19th 2014

Juno Therapeutics, Inc, has filed a registration statement for an initial public offering of its common stock, as its early stage therapies continue to advance in clinical trials.

Bringing CARs to Market: Novel T-Cell Therapies Make Rapid Progress Despite Challenges

November 18th 2014

When Marcela V. Maus, MD, PhD, thinks of the challenge of bringing chimeric antigen receptor (CAR) therapies to market in the battle against cancer, she is reminded of the auto industry's first days.

Dr. Jain on Increased Lymphocytosis Following Treatment With a B-Cell Receptor Inhibitor

November 5th 2014

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.

TGR-1202 and Ublituximab Show Promise in CLL

November 5th 2014

As the targeted therapy era in chronic lymphocytic leukemia (CLL) continues to unfold, two next-generation agents are generating responses with improved safety profiles as single agents and in combination regimens

European Commission Approves Ibrutinib for MCL, CLL

October 21st 2014

Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.

New Strategies Emerge for Managing CLL Patients in Community Settings

October 20th 2014

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) is rapidly changing, with the emergence of four new therapeutic options for this malignancy in recent months.

Infinity Inks Deals to Expand Research Into Duvelisib

September 23rd 2014

Infinity Pharmaceuticals has entered into two separate agreements with Roche and AbbVie to develop and commercialize duvelisib (IPI-145), an oral inhibitor of PI3K-delta and PI3K-gamma, for the treatment of patients with hematologic malignancies.

FDA Grants Special Protocol Assessment to Phase III Ublituximab/Ibrutinib Study

September 21st 2014

TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

September 18th 2014

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.

Dr. John Byrd Discusses the Treatment Landscape for CLL

September 9th 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising treatment landscape for patients with chronic lymphocytic leukemia.